AbelZeta Pharma Announces Stem Cell Business Spin-off and Launch of New Corporate Identity
AbelZeta
Developer of Immune Cell and Stem Cell Therapy Products
Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to drugs related to healthcare (if applicable); it does not recommend any treatment plans. This article does not constitute any investment advice.
Mr. Liu Bizuo, Chairman and Chief Executive Officer of Cellular Biomedicine Group (Shanghai) Ltd, stated:This marks that Cellular Biomedicine Group, as an innovative immunocyte therapy company, is about to enter a brand-new stage of commercial development. Zeta is a well-known key component of the T-cell receptor in immunocytes. Combined, AbelZeta represents our confidence in immunocyte therapy and the future direction of the company.
Cellular Biomedicine Group's immunocyte therapy pipeline includes 10 programs that have entered clinical trials in both China and the United States.
About Cellular Biomedicine Group
Cellular Biomedicine Group is a clinical-stage global biopharmaceutical company with innovation centers in Shanghai, China, and Maryland, USA. It focuses on developing innovative cell therapy products and is committed to combating malignant hematologic tumors, solid tumors, inflammation, and immune diseases through personalized treatments that harness the body's own immune system. The company has GMP-compliant production facilities at each of its innovation centers to advance product development and early clinical research, with a pipeline covering CAR-T and TIL therapies.